You just read:

Pearl Therapeutics' Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD

News provided by

Pearl Therapeutics

May 18, 2011, 10:15 ET